Farmacovigilancia: ¿y si notificamos?

Autor: Rosario Rodríguez Rodríguez, Clara Alonso Larrocha, Ana María Rivera Bocanegra, Estefanía Bravo Moreno, Tomás Tena Trincado, Ana Isabel Beas Morales
Jazyk: Spanish; Castilian
Rok vydání: 2014
Předmět:
Zdroj: Farmacéuticos Comunitarios, Vol 6, Iss 2, Pp 48-52 (2014)
Farmacéuticos Comunitarios; Vol. 6, Núm. 2 (2014); p. 48-52
ISSN: 2173-9218
1885-8619
Popis: espanolRESUMEN Introduccion: Farmacovigilancia es la actividad de salud publica que tiene como objetivo la identificacion, cuantificacion, evaluacion y prevencion de los riesgos del uso de los medicamentos una vez comercializados, permitiendo asi el seguimiento de los posibles efectos adversos. Segun las ultimas estadisticas del Centro Andaluz de Farmacovigilancia las notificaciones por farmaceuticos solo suponen el 9% de las realizadas por los profesionales sanitarios. A la vista de estos datos se propuso un estudio para conocer los motivos de la falta de notificacion y resolver los posibles problemas. Metodo: Se elaboro un cuestionario ad hoc, que se envio a todos los farmaceuticos de la provincia de Huelva. Resultados: Participaron 66 farmaceuticos. El 91% conoce la tarjeta amarilla, dispone de ella el 45%, conoce la via web el 34%, ha notificado alguna vez 34% (7% lo hace siempre que se encuentra una reaccion adversa). El 60% no ha notificado nunca y un 15% piensa que no es obligatorio. Los motivos por los que no se notifica son falta de informacion 44%, falta de formacion 41%, falta de tiempo 36% y no disponer de tarjeta amarilla 29%. Los titulares demandan una mayor informacion y formacion. Los adjuntos ven la falta de tiempo como principal motivo de la no notificacion. Discusion: Ante la poca notificacion por los farmaceuticos y la importancia de este tema, se propone una campana de concienciacion entre los farmaceuticos de Huelva para mejorar estos resultados. Para ello se enviara a todos los colegiados un d EnglishIntroduction: Pharmacovigilance is the public health activity that identifies, quantifies, evaluates and prevents the risks of the use of medicines after their introduction upon the market, thus allowing follow-up of their possible adverse effects. According to the latest statistics of the Andalusian Pharmacovigilance Center, reports by pharmacists represent only 9% of all reports by health professionals. In view of these data, a study was designed to identify the reasons for this lack of reporting and resolve the possible problems. Method: An ad hoc questionnaire was administered among all the pharmacists of the province of Huelva (Spain). Results: Sixty-six pharmacists participated in the study. A full 91% were aware of the yellow card pharmacovigilance reporting system, 45% were in possession of the card, 34% knew of the system website, and 34% had made use of the system for reporting (7% claimed to do so each time they identified an adverse reaction). Sixty percent had never reported, and 15% believed that reporting is not mandatory. The reasons for not reporting were lack of information (44%), lack of training (41%), lack of time (36%) and non-availability of the yellow card (29%). The pharmacy owners expressed a need for greater information and training. The pharmacy employees regarded a lack of time to be the main reason for not reporting adverse reactions. Discussion: In view of the low reporting levels among pharmacists and the great importance of this subject, we recommend the introduction of an awareness-enhancing campaign among the pharmacists in Huelva in order to improve the results obtained. In this regard, all the pharmacists will receive an informative leaflet with the aim of solving the main inconveniences of reporting.
Databáze: OpenAIRE